Sopaan Pharmaceuticals Limited has opened its Initial Public Offering (IPO) to the general public starting April 16, 2026. This important announcement gives Nepalese investors an opportunity to participate in the company’s growth by subscribing to its IPO shares.
The company has received approval from the Securities Board of Nepal (SEBON) to issue shares worth NPR 171.60 crore, which represents 25% of its total paid-up capital. Of this amount, the first portion of shares has already been allocated to overseas Nepalese investors, collective investment funds, and company employees.
Company’s IPO Details
Under the SEBON-approved plan, Sopaan Pharmaceuticals is now issuing 3,474,900 ordinary shares to the public at a face value of NPR 100 per share.
Investors interested in applying must submit their applications between April 16 and April 22, 2026. If the total demand does not reach required levels by April 22, the IPO subscription period may be extended until April 29, 2026.
Shares can be applied through:
- All SEBON-registered brokers and their designated branches
- The Mero Share website
- The Mero Share mobile app
These options provide flexibility whether you prefer online or in-person subscription.
Minimum & Maximum Shares You Can Apply For
Sopaan Pharmaceuticals has set a minimum application requirement of 10 shares per investor. Those who wish to subscribe for more may apply for up to a maximum of 11,000 shares.
In case the IPO is oversubscribed, shares will be allocated through the standard lottery (ballot) system described in the Nepalese securities regulations. As per preliminary estimates, about 347,490 applicants may receive shares if they apply for the minimum number (10 shares).
Credit Rating & Risk Assessment
Before issuing shares to the general public, the company’s creditworthiness was evaluated in accordance with regulatory requirements. CARE Ratings Nepal has given Sopaan Pharmaceuticals a moderate risk rating, indicating a medium level of financial risk relative to its operations and obligations.
Company Background: Who Is Sopaan Pharmaceuticals?
Sopaan Pharmaceuticals Limited was registered as a public company with the Office of the Company Registrar on September 21, 2009. Over the years, it has obtained various approvals from the Government of Nepal and relevant authorities to operate as a pharmaceutical manufacturer and supplier across the country.
The company’s registered office is located in Lalitpur District (Mahalaxmi Municipality Ward No. 8), and its corporate office is in Tinkune, Kathmandu. The business produces and distributes a range of medicines and healthcare products throughout Nepal.
In addition, Sopaan has expanded operations into related sectors. For example, its affiliate Sopaan Oxygen Limited has completed environmental clearance processes for oxygen and nitrogen gas production facilities to support both healthcare needs and industrial demand.
Purpose of the IPO
The company has stated that the primary purposes of issuing this IPO are:
- To raise capital for debt repayment
- To finance new manufacturing projects
- To purchase advanced production equipment
- To expand overall production capacity
These investments are expected to improve operational efficiency and support long-term growth.
Financial Snapshot & Future Outlook
According to financial data available up to the latest reporting period:
- Net asset value per share stands at a competitive level.
- Earnings per share (EPS) reflect ongoing profitability.
- The company also maintains a healthy reserve fund, which provides a cushion against operational risks.
Although pharmaceutical companies can face regulatory, market, and competitive challenges, Sopaan’s strategy to diversify products and improve production infrastructure could support future revenue growth.
What This Means for Investors
For those considering an IPO application:
- Ensure you understand the minimum & maximum subscription limits.
- Review your investment goals, especially if you plan to hold shares long-term after listing.
- Remember that IPOs in Nepal are often oversubscribed, and allocation is based on ballot results.
For the quickest way to check your allotment status after applying, use a reliable IPO tracking tool like https://iporesult.freerojgari.com right after results are published.
Summary
Sopaan Pharmaceuticals Limited’s IPO presents a potential opportunity for retail investors in Nepal to participate in the pharmaceutical sector’s growth. With a clear regulatory roadmap and a wide offering window, investors should carefully assess both the company fundamentals and their personal investment strategies before subscribing.